Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-γ1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line

被引:18
作者
Cianfriglia, Maurizio [1 ]
Mallano, Alessandra [1 ]
Ascione, Alessandro [1 ]
Dupuis, Maria Luisa [1 ]
机构
[1] Ist Super Sanita, Sect Pharmacogenet Drug Resistance & Expt Therape, Dept Therapeut Res & Med Evaluat, I-00161 Rome, Italy
关键词
multi-drug resistance; calicheamicin; tumor-targeting; immunoconjugates; gentuzumab ozogamicin; ACUTE MYELOID-LEUKEMIA; GEMTUZUMAB OZOGAMICIN; P-GLYCOPROTEIN; TARGETED CHEMOTHERAPY; INDUCED CYTOTOXICITY; MONOCLONAL-ANTIBODY; DESIGNED ENEDIYNES; CD33; EXPRESSION; EFFICACY; CANCER;
D O I
10.3892/ijo_00000638
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this study we elucidated the role of ATP-binding cassette (ABC) multi-drug transporter proteins and cellular factors such as Bcl-2 expression and CD33 down-modulation contributing to free and hP67.6 mAb linked calicheamicin-gamma 1 (CalC-gamma 1) resistance. We analyzed in a well designed HL60 cell system the relationship between the expression of ABC proteins, Bcl-2 and CD33 modulation with the activity of free and mAb-linked CalC-gamma 1. The results herein reported and discussed, strongly suggest that both MDR1-Pgp and MRP1 efflux systems are engaged by CalC-gamma 1, but only MDR1-Pgp over-expression efficiently abrogates drug cytotoxicity in MDR cells. Paradoxically, Bcl-2 expression, as observed for other anticancer compounds belonging to the enediyne family of drugs, confers CalC-gamma 1 susceptibility rather than resistance in HL60 cells. Further, the isolation of a resistant HL60 subline (HL60AL) that was developed by exposing the parental sensitive cells to sub-effective doses of gemtuzumab ozogamicin (GO) over an extended period of time shows a reduced level of CD33 expression that represents an important escape mechanism of HL60 MDR cells to the cytotoxic effect of GO.
引用
收藏
页码:1513 / 1520
页数:8
相关论文
共 33 条
  • [1] MRP3, BCRR and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia
    Benderra, Z
    Faussat, AM
    Sayada, L
    Perrot, JY
    Tang, RP
    Chaoui, D
    Morjani, H
    Marzac, C
    Marie, JP
    Legrand, O
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (21) : 7764 - 7772
  • [2] BROCK I, 1995, CANCER RES, V55, P459
  • [3] CIANFRIGLIA M, 1994, INT J CANCER, V56, P153
  • [4] Tumour-targeted chemotherapy with immunoconjugates of calicheamicin
    Damle, NK
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (09) : 1445 - 1452
  • [5] Substrate recognition and transport by multidrug resistance protein 1 (ABCC1)
    Deeley, RG
    Cole, SPC
    [J]. FEBS LETTERS, 2006, 580 (04) : 1103 - 1111
  • [6] Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma
    DiJoseph, JF
    Dougher, MM
    Kalyandrug, LB
    Armellino, DC
    Boghaert, ER
    Hamann, PR
    Moran, JK
    Damle, NK
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (01) : 242 - 249
  • [7] CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab
    DiJoseph, John F.
    Dougher, Maureen M.
    Armellino, Douglas C.
    Kalyandrug, Lyka
    Kunz, Arthur
    Boghaert, Erwin R.
    Hamann, Philip R.
    Damle, Nitin K.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (07) : 1107 - 1117
  • [8] FLENS MJ, 1994, CANCER RES, V54, P4557
  • [9] Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia
    Goemans, B. F.
    Zwaan, C. M.
    Vijverberg, S. J. H.
    Loonen, A. H.
    Creutzig, U.
    Harhlen, K.
    Reinhardt, D.
    Gibson, B. E. S.
    Cloos, J.
    Kaspers, G. J. L.
    [J]. LEUKEMIA, 2008, 22 (12) : 2284 - 2285
  • [10] Multidrug resistance in cancer: Role of ATP-dependent transporters
    Gottesman, MM
    Fojo, T
    Bates, SE
    [J]. NATURE REVIEWS CANCER, 2002, 2 (01) : 48 - 58